Loading...
Market
How many pharmaceutical companies will release new treatments for Alzheimer's following early diagnosis by the end of 2025?
2
Resolution / Starting Odds
None • 25%
1-2 companies • 25%
3-4 companies • 25%
More than 4 companies • 25%
FDA approvals and company press releases
Story
New Blood Test Shows 90% Accuracy in Diagnosing Alzheimer's, JAMA Study Presented at AAIC 2024
Jul 28, 2024, 08:25 PM
A new blood test has shown promise in diagnosing Alzheimer's disease with 90% accuracy, outperforming traditional cognitive tests and CT scans. This development represents a significant step forward in the affordable and accessible diagnosis of Alzheimer's. The findings, presented at the Alzheimer’s Association International Conference (AAIC) 2024, suggest that blood tests could improve diagnosis in primary care, making testing less invasive and more accessible. The tests measure biomarkers such as phosphorylated tau and amyloid-beta, which are linked to Alzheimer's. Researchers reported that the blood test was significantly more accurate than doctors' interpretation of cognitive tests and CT scans. This advancement could lead to early diagnosis and timely access to new treatments, potentially accelerating research participation and treatment for millions. A JAMA study highlighted C2N Diagnostics’ PrecivityAD2™ blood test, which markedly improves accuracy of Alzheimer's diagnosis. The study involved about 1,200 patients in Sweden.
View original story
Similar markets
0-1 new treatments • 25%
2-3 new treatments • 25%
4-5 new treatments • 25%
More than 5 new treatments • 25%
More than 3 competitors • 25%
2 to 3 competitors • 25%
1 competitor • 25%
No new competitors • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
No new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more new competitors • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
Yes • 50%
No • 50%
0-5 • 25%
6-10 • 25%
11-15 • 25%
16 or more • 25%
0-10 • 25%
11-20 • 25%
21-30 • 25%
31 or more • 25%
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%